Exact Mass: 499.35088440000004
Exact Mass Matches: 499.35088440000004
Found 143 metabolites which its exact mass value is equals to given mass value 499.35088440000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine
C31H49NO4 (499.36613940000007)
(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(7Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-7,9,12,15,18,21-hexaenoylcarnitine
C31H49NO4 (499.36613940000007)
(7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-[(1R,2R,3R)-3-Hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine
C27H49NO7 (499.35088440000004)
7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5E)-7-[3,5-Dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine
C27H49NO7 (499.35088440000004)
(5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine
C30H45NO5 (499.32975600000003)
(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10E,12E,16Z)-18-(3-ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
1H-Benzimidazole-2-carboxamide, 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-((3S,5R)-5-(4-morpholinylcarbonyl)-3-piperidinyl)-
C27H41N5O4 (499.31583860000006)
Ile Ile Arg Val
Ile Ile Val Arg
Ile Leu Arg Val
Ile Leu Val Arg
Ile Arg Ile Val
Ile Arg Leu Val
Ile Arg Val Ile
Ile Arg Val Leu
Ile Val Ile Arg
Ile Val Leu Arg
Ile Val Arg Ile
Ile Val Arg Leu
Lys Lys Lys Pro
Lys Lys Pro Lys
Lys Lys Pro Gln
C22H41N7O6 (499.31181660000004)
Lys Lys Gln Pro
C22H41N7O6 (499.31181660000004)
Lys Pro Lys Lys
Lys Pro Lys Gln
C22H41N7O6 (499.31181660000004)
Lys Pro Gln Lys
C22H41N7O6 (499.31181660000004)
Lys Gln Lys Pro
C22H41N7O6 (499.31181660000004)
Lys Gln Pro Lys
C22H41N7O6 (499.31181660000004)
Leu Ile Arg Val
Leu Ile Val Arg
Leu Leu Arg Val
Leu Leu Val Arg
Leu Arg Ile Val
Leu Arg Leu Val
Leu Arg Val Ile
Leu Arg Val Leu
Leu Val Ile Arg
Leu Val Leu Arg
Leu Val Arg Ile
Leu Val Arg Leu
Pro Lys Lys Lys
Pro Lys Lys Gln
C22H41N7O6 (499.31181660000004)
Pro Lys Gln Lys
C22H41N7O6 (499.31181660000004)
Pro Gln Lys Lys
C22H41N7O6 (499.31181660000004)
Gln Lys Lys Pro
C22H41N7O6 (499.31181660000004)
Gln Lys Pro Lys
C22H41N7O6 (499.31181660000004)
Gln Pro Lys Lys
C22H41N7O6 (499.31181660000004)
Arg Ile Ile Val
Arg Ile Leu Val
Arg Ile Val Ile
Arg Ile Val Leu
Arg Leu Ile Val
Arg Leu Leu Val
Arg Leu Val Ile
Arg Leu Val Leu
Arg Val Ile Ile
Arg Val Ile Leu
Arg Val Leu Ile
Arg Val Leu Leu
Val Ile Ile Arg
Val Ile Leu Arg
Val Ile Arg Ile
Val Ile Arg Leu
Val Leu Ile Arg
Val Leu Leu Arg
Val Leu Arg Ile
Val Leu Arg Leu
Val Arg Ile Ile
Val Arg Ile Leu
Val Arg Leu Ile
Val Arg Leu Leu
Ethanol, 2,2-(2-heptadecyl-4(5H)-oxazolylidene)bis(methyleneoxy-2,1-ethanediyloxy)bis-
tert-butyl 4-((S)-4-((R)-2-Methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-3-Methylpiperazin-1-yl)-4-Methylpiperidine-1-carboxylate
C26H40F3N3O3 (499.3021606000001)
1H-Benzimidazole-2-carboxamide, 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-((3S,5R)-5-(4-morpholinylcarbonyl)-3-piperidinyl)-
C27H41N5O4 (499.31583860000006)
7-[(1R,2R,3R)-3-Hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine
C27H49NO7 (499.35088440000004)
(5E)-7-[3,5-Dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine
C27H49NO7 (499.35088440000004)
(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine
C31H49NO4 (499.36613940000007)
(7Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-7,9,12,15,18,21-hexaenoylcarnitine
C31H49NO4 (499.36613940000007)
(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine
C30H45NO5 (499.32975600000003)
N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C29H45N3O4 (499.34098900000004)
N-[(5R,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C29H45N3O4 (499.34098900000004)
N-[(5S,6S,9S)-8-(2-cyclopropylacetyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5S,6R,9R)-8-(2-cyclopropyl-1-oxoethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5S,6S,9R)-8-(2-cyclopropylacetyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5R,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C29H45N3O4 (499.34098900000004)
N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C29H45N3O4 (499.34098900000004)
N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C29H45N3O4 (499.34098900000004)
N-[(5R,6S,9R)-8-(2-cyclopropyl-1-oxoethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5S,6S,9S)-8-[cyclohexyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5S,6R,9S)-8-(2-cyclopropyl-1-oxoethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5R,6R,9S)-8-(2-cyclopropyl-1-oxoethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5R,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C29H45N3O4 (499.34098900000004)
N-[(5R,6R,9R)-8-(2-cyclopropyl-1-oxoethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopentanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5R,6R,9R)-8-[cyclohexyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5R,6S,9R)-8-[cyclohexyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C28H41N3O5 (499.30460560000006)
N-[(5S,6R,9S)-8-[cyclohexyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C28H41N3O5 (499.30460560000006)
[2-hydroxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C26H46NO6P (499.30625860000004)
(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxypentadeca-4,8,12-triene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(4E,8E,12E)-2-(decanoylamino)-3-hydroxyheptadeca-4,8,12-triene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
C27H49NO5S (499.3331264000001)
2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyundecane-1-sulfonic acid
C27H49NO5S (499.3331264000001)
4-[3-butanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
C27H49NO7 (499.35088440000004)
4-[3-propanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
C27H49NO7 (499.35088440000004)
4-[3-acetyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
C27H49NO7 (499.35088440000004)
2-({1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]butylidene}amino)-n-(1-hydroxy-2-oxopentadecyl)-3-methylbutanimidic acid
C26H49N3O6 (499.36211740000005)